Clinical Trial

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Study acronym: ARTISAN
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 9, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2022-01-10; most recent amendment 2025-12-02.
Status change: Recruiting → Active, Not Recruiting 2025-04-08
Status change: Not Yet Recruiting → Recruiting 2022-09-07
Trial Details
NCT Number NCT05203510
Lead Sponsor United Therapeutics
Collaborators: Lung Biotechnology PBC
Conditions Pulmonary Arterial Hypertension
Enrollment 52 participants
Start Date 2022-10-20
Primary Completion 2026-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-09